IGF1R and rhabdomyosarcoma: In addition, treatment of rhabdomyosarcoma cells with anti-IGF-IR mAb or IGF-IR/IR kinase inhibitor leads to increased activation of YES/Src family tyrosine kinase (SFK) [173].